A Guide to Asthma and COPD Maintenance Therapy by Alyssa Lagasca, PharmD

	a cor b maintenance merapy by myssa	
Asthma	Therapies and counseling points	COPD
Track 1 (preferred - Symbicort):	ICS – thrush (rinse mouth), cough and throat irritation	0 or 1 moderate exacerbations
1) PRN only low dose ICS-formoterol	Flovent (Fluticasone Propionate)	mmRC 0-1, CAT < 10: LABA (prefer) or
2) PRN only low dose ICS-formoterol	Pulmicort (Budesonide)	SABA
3) Low dose maintenance ICS-formoterol	QVAR (Beclomethasone)	mmRC \geq 2, CAT \geq 10: LABA + LAMA
4) Medium dose maintenance ICS-formoterol		
5) Add-on LAMA and <u>consider</u> high dose ICS -	LABA – tremors and palpitations	>2 moderate exacerbations OR > 1
formoterol (+/-) anti-IgE, anti-IL5/5R	Performoist (formoterol)	leading to hospitalization:
	Serevent Diskus (salmeterol)	Regardless of mmRC/CAT: LABA +
Track 2:		LAMA
1) ICS whenever SABA is taken for	LAMA – dry mouth, urinary retention and constipation	If blood eos \geq 30: LABA + LAMA + ICS
exacerbation.	Incruse (umeclidinium)	
2) Low dose maintenance ICS	Spiriva (tiotropium)	Management cycle:
3) Low dose maintenance ICS-LABA		1) Review Symptoms such as
4) Medium/high dose maintenance ICS-	ICS-LABA	dyspnea (mmRC*/CAT**) and
LABA	Symbicort (Budesonide/Formoterol)	exacerbations
5) Same as track 1 (Add-on LAMA with	Advair (Fluticasone/Salmeterol)	
consideration for high dose ICS-LABA)	Breo Ellipta (Fluticasone/Vilanterol)	2) Assess:
		 Inhaler technique and
Management cycle:	LAMA-LABA	adherence
1) Review symptoms, exacerbations, side	Anoro Ellipta (Umeclidinium/Vilanterol)	 Non-pharmacological
effects, lung function and patient	Stiolto Respimat (Olodaterol/Tiotropium)	approaches (pulmonary
satisfaction		rehabilitation and self-
2) Assess symptom control/modifiable risk	ICS-LABA-LAMA	management education)
factors, inhaler technique/adherence	Trelegy Ellipta (Fluticasone/Vilanterol/Umeclidinium)	
3) Adjust based on observations from steps	Breztri Aerosphere	3) Escalate or de-escalate based on
1&2	(Budesonide/Glycopyrrolate/Formoterol)	observations from steps 1&2

*mmRC: modified Medical Research Council dyspnea scale

^{**}CAT: COPD assessment test

MDIs (Metered Dose Inhalers)	DPIs (Dry Powder Inhalers)	
Key is to inhale <u>SLOW AND DEEP.</u>	Key is to inhale FORCEFULLY and DEEP.	
Administration:	Handihaler Administration:	
1. For first time use or if not used for 7+	 Insert capsule into chamber. Press green button once to puncture capsule and release medicine. 	
days, prime inhaler by shaking it well	3. Do NOT shake device, breathe out fully.	
for 5 seconds then release a test	4. Inhale fast and deep into mouthpiece.	
	5. Remove inhaler from mouth and hold breath for 10 seconds.	
Spray.	6. Breathe out slowly and repeat steps 4-8 to get full dose.	
2. Shake inhaler and remove protective	Filiate Administration.	
cap.	Ellipta Administration:	
3. Hold inhaler upright and exhale away	 Slide cover down to expose mouthpiece, do not block air vent. Do NOT shake device, breathe out fully. 	
from device.	3. Take a forceful and quick breath into mouthpiece.	
4. Place mouthpiece between lips and	4. Remove inhaler from mouth and hold breath for 3-4 seconds before breathing out	
teeth.	and sliding cover back on.	
5. Inhale slowly and deeply and press	Diskus Administration:	
down on the canister to receive	1. Push thumb grip away from you until it clicks, this will allow you to see mouthpiece.	
medication.	 Hold the lever and slide lever away from you until Diskus clicks – this will load medication. 	
6. Hold breath for 5-10 seconds before	3. Breathe out and seal lips around mouthpiece.	
	4. Inhale rapidly and deeply then continue to take a full, deep breath.	
re-capping and breathing out.	5. Hold breath for 10 seconds before breathing out, then pushing thumb grip back to	
	you to close mouthpiece.	

References:

- **1.** Venkatesan P. 2023 GINA report for asthma. Lancet Respir Med. 2023 Jul;11(7):589. doi: 10.1016/S2213-2600(23)00230-8. Epub 2023 Jun 8. PMID: 37302397.
- **2.** Venkatesan P. GOLD COPD report: 2023 update. Lancet Respir Med. 2023 Jan;11(1):18. doi: 10.1016/S2213-2600(22)00494-5. Epub 2022 Nov 30. PMID: 36462509.